Biotech RadarJobs updated

COMPANY

Intellia Therapeutics

HQ: Cambridge, MA source · intelliatx.com ↗ · New England

Clinical Phase 3

16 open jobs · last seen Oct 23, 2026 · 12 sources

Keywords: CRISPR hematology factor VIII deficiency hemophilia B Hereditary Angioedema Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy Wild-Type Transthyretin Cardiac Amyloidosis Neuromuscular Disease Neuromuscular Diseases Neurodegenerative Disease Hereditary Neurodegenerative Disease Neurodegenerative Diseases Nerve Disorders Nervous System Disease Nervous System Diseases Inborn Genetic Disease Familial Amyloidosis Hereditary Amyloidosis Amyloidosis Polyneuropathies Amyloid Neuropathies Familial Amyloid Neuropathies Peripheral Nervous System Disease Peripheral Nervous System Diseases Inborn Errors Metabolism Metabolic Diseases Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Lung Disease Pulmonary Disease AATD Alpha-1 Antitrypsin Deficiency Alpha-1 Antitrypsin Deficiency-associated Lung Disease Acute Myeloid Leukemia NTLA-2001 NTLA-2002 nexiguran ziclumeran

Profile checked Oct 10, 2026

Since the raise (Apr 29, 2026): 16 of 16 open jobs were first seen after it.

16Open jobs$180.0MRaised (2 yrs)9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Head of Clinical DevelopmentCambridge, MAOct 22, 2026Oct 23, 2026
Associate Director Meetings and CongressesCambridge, MAOct 22, 2026Oct 23, 2026
Head of Clinical DevelopmentCambridge, MAOct 16, 2026Oct 16, 2026
Director, Alternative Site of Care Strategy LeadCambridge, MAOct 13, 2026Oct 14, 2026
Director Risk and Compliance OperationsCambridge, MAOct 5, 2026Oct 9, 2026

See all 16 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (16 open jobs at last check). source ↗
  2. Debt Debt financing: $400M (up to, as announced), announced Sep 4, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $180M (total, as published), announced Apr 29, 2026. Source: company release on GlobeNewswire. source ↗
  4. Trial start 3: HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) source ↗
  5. Trial start 3: A Phase 3 Study of NTLA-2001 in ATTRv-PN source ↗
  6. Trial start Phase 1/Phase 2: NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease source ↗
  7. Trial start —: Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 source ↗
  8. Trial start 3: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) source ↗
  9. Trial start —: Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 source ↗
  10. Trial start Phase 1/Phase 2: Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia source ↗
  11. Trial start Phase 1/Phase 2: NTLA-2002 in Adults With Hereditary Angioedema (HAE) source ↗
  12. Trial start Phase 1: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients W source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 16

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Head of Clinical DevelopmentCambridge, MAOct 22, 2026Oct 23, 2026Not stated
Associate Director Meetings and CongressesCambridge, MAOct 22, 2026Oct 23, 2026Not stated
Head of Clinical DevelopmentCambridge, MAOct 16, 2026Oct 16, 2026Not stated
Director, Alternative Site of Care Strategy LeadCambridge, MAOct 13, 2026Oct 14, 2026Senior
Director Risk and Compliance OperationsCambridge, MAOct 5, 2026Oct 9, 2026Senior
Sr. Intellectual Property (“IP”) CounselCambridge, MAOct 1, 2026Oct 9, 2026Senior
Manager CMC Program OperationsCambridge, MASep 23, 2026Oct 9, 2026Mid
Senior Manager, ContractsCambridge, MASep 23, 2026Oct 9, 2026Senior
Senior Director, Global Brand and US Marketing Lead (ATTR)Cambridge, MASep 23, 2026Oct 9, 2026Senior
Senior Scientist - Small Molecule and Oligonucleotide Process SciencesCambridge, MASep 23, 2026Oct 9, 2026Senior
Head of Medical AffairsCambridge, MASep 23, 2026Oct 9, 2026Executive
Regional Scientific Director, Mid-AtlanticCambridge, MASep 23, 2026Oct 9, 2026Senior
Strategic Account Liaison - Ohio ValleyCambridge, MASep 23, 2026Oct 9, 2026Senior
Associate Director, HCP Personal PromotionCambridge, MASep 23, 2026Oct 9, 2026Senior
Vice President, Quality Management Systems and Digital ComplianceCambridge, MASep 23, 2026Oct 9, 2026Executive
Vice President, Gene Editing CoreCambridge, MASep 23, 2026Oct 9, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $180.0M · Debt: $400.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT06634420HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)3Active, not recruitingJan 15, 2025Feb 10, 2026 (actual)
NCT05120830NTLA-2002 in Adults With Hereditary Angioedema (HAE)Phase 1/Phase 2Active, not recruitingDec 10, 2021Apr 4, 2024 (actual)
NCT05697861Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001Not listedEnrolling by invitationJul 10, 20232038-03 (estimated)
NCT06672237A Phase 3 Study of NTLA-2001 in ATTRv-PN3RecruitingNov 22, 20242027-07 (estimated)
NCT06128629MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)3RecruitingDec 13, 20232027-12 (estimated)
NCT04601051Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)Phase 1CompletedNov 5, 2020Sep 12, 2025 (actual)
NCT06262399Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002Not listedEnrolling by invitationApr 12, 20242040-04 (estimated)
NCT06622668NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseasePhase 1/Phase 2WithdrawnNov 20, 2024Jan 9, 2025 (estimated)
NCT05066165Study Investigating NTLA-5001 in Subjects With Acute Myeloid LeukemiaPhase 1/Phase 2TerminatedDec 17, 2021Jul 21, 2022 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Intellia Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback